Cancer treatment and research communications最新文献

{"title":"Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer. Are we looking at the tumor or the patient's immune response to the tumor?","authors":"Caroline B. van den Berg ,&nbsp;Gatske M. Nieuwenhuyzen-de Boer ,&nbsp;Ingrid A. Boere ,&nbsp;Ruben G. Boers ,&nbsp;Joachim B. Boers ,&nbsp;Wilfred F.J. van-IJcken ,&nbsp;Maurice P.H.M. Jansen ,&nbsp;Tugce S. Kirmizitas ,&nbsp;Joost H. Gribnau ,&nbsp;Heleen J. van Beekhuizen","doi":"10.1016/j.ctarc.2025.100903","DOIUrl":"10.1016/j.ctarc.2025.100903","url":null,"abstract":"<div><div>The aim of this study was to identify differentially methylated regions in cell-free DNA (cfDNA) between healthy persons and patients with advanced stage ovarian cancer (ASOC) and to identify differences in cfDNA methylation before and after cytoreductive surgery. Plasma-derived cfDNA was analyzed by a high-throughput genome wide DNA methylation sequencing technique: MeD-seq. A training set of therapy naïve cfDNA samples of patients with ASOC (≥FIGO stage IIIB, n=10) was compared with cfDNA of healthy controls (n=10) to define a ASOC specific cfDNA methylation signature. A cumulative hypermethylation score was constructed and a validation set of pre- and postoperative samples of 39 patients were compared using this score. MeD-seq results of tumor tissue samples were correlated with cfDNA results. Patients with ASOC showed a clear distinct cfDNA methylation signature from healthy controls (p&lt;0.0001). This cfDNA-methylation signature resulted in preoperative hypermethylation scores (135; interquartile range 110–163) that were significantly higher than postoperative hypermethylation scores (91; interquartile range 76–101) (p&lt;0.001). The cfDNA methylation signature at baseline differed from tumor tissue and was more closely related to DNA methylation of immune-related cells (T-lymphocytes, neutrophil granulocytes, monocytes, and B-lymphocytes) than to ASOC tissue.</div><div>MeD-seq provides a promising method for genome wide methylation profiling of cfDNA. Patients with ASOC could clearly be distinguished from healthy controls and differed pre- and postoperatively.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100903"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1","authors":"M Sereno ,&nbsp;A Collazo-Lorduy ,&nbsp;Y Garitaonaindia ,&nbsp;D Gómez de Antonio ,&nbsp;J Baena Espinar ,&nbsp;C Aguado de la Rosa ,&nbsp;P Cruz Castellanos ,&nbsp;S Falagán Martínez ,&nbsp;LE Chara Valverde ,&nbsp;R López-Castro ,&nbsp;A López-Martin ,&nbsp;J Rubio-Pérez ,&nbsp;A Gómez Rueda ,&nbsp;C Traseira Puchol ,&nbsp;X Mielgo Rubio ,&nbsp;B Losada Vila ,&nbsp;J Rogado ,&nbsp;E Bernal Hertfelder ,&nbsp;L Gutiérrez Sainz ,&nbsp;JL Campo-Cañaveral ,&nbsp;E Casado Sáenz","doi":"10.1016/j.ctarc.2025.100910","DOIUrl":"10.1016/j.ctarc.2025.100910","url":null,"abstract":"<div><h3>Background</h3><div>The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.</div></div><div><h3>Methods</h3><div>From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.</div></div><div><h3>Results</h3><div>Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, <em>p</em> = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, <em>p</em> = 0.001) and FVC (+3.7 % vs. -0.7 %, <em>p</em> = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.</div></div><div><h3>Conclusions</h3><div>CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100910"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer","authors":"Seung Ho Baek ,&nbsp;Soong June Bae ,&nbsp;Yoonwon Kook ,&nbsp;Yeona Cho ,&nbsp;Sung Gwe Ahn ,&nbsp;Jun Won Kim ,&nbsp;Ik Jae Lee ,&nbsp;Joon Jeong","doi":"10.1016/j.ctarc.2025.100925","DOIUrl":"10.1016/j.ctarc.2025.100925","url":null,"abstract":"<div><h3>Background</h3><div>Although the use of intraoperative radiotherapy (IORT) for accelerated partial breast irradiation is growing, there are not many studies on its effectiveness specifically in Asian population. In this study, we aimed to investigate the long-term oncologic outcomes of Korean patients who received IORT with low-energy X-ray as a tumor-bed boost.</div></div><div><h3>Methods</h3><div>We conducted phase II, prospective, single-arm trial to evaluate the local toxicity and oncologic outcomes in breast cancer patients receiving IORT with low-energy X-rays as a tumor-bed boost (NCT02213991). Patients underwent IORT as a tumor-bed boost with low-energy X-rays (20 Gy) followed by external beam radiotherapy for whole breast irradiation (46 Gy). Patients diagnosed with early-stage breast cancer or ductal carcinoma in situ who were suitable for lumpectomy were considered eligible. Kaplan-Meier analysis was used to assess oncologic outcomes with an extended follow-up period.</div></div><div><h3>Results</h3><div>A total of 194 patients underwent IORT between August 2014 and September 2016 according to the protocol outlined in our study. During the median follow-up of 85.6 months, 12 cases (6.19 %) of recurrence were reported, of which 4 (2.06 %) were reported ipsilateral breast tumor recurrence (IBTR) as the first recurrence event. The 5- and 8-year IBTR rates were both 2.1 % (95 % confidence intervals (CIs), 93.8 – 98.9). The 5-year loco-regional recurrence-free survival (LRRFS), recurrence-free survival (RFS), and overall survival (OS) rates were 97.37 %, 96.32 %, and 100 %, respectively.</div></div><div><h3>Conclusion</h3><div>We identified the oncologic safety of IORT with low-energy X-rays as a tumor-bed boost in Korean patients during an extended follow-up period.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100925"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The symptom burden of women with a known risk of breast cancer receiving risk reducing medication","authors":"Meagan S. Whisenant ,&nbsp;Jessica Treviño Jones ,&nbsp;Anneliese O. Gonzalez ,&nbsp;Therese Bartholomew Bevers ,&nbsp;Kelly Brassil ,&nbsp;Darcy A. Ponce ,&nbsp;Sharvari Kamat ,&nbsp;Emily Solis ,&nbsp;Ann Maliackal ,&nbsp;Hannah Warlick ,&nbsp;Amie Walters ,&nbsp;Chloe Denham ,&nbsp;Loretta A. Williams","doi":"10.1016/j.ctarc.2023.100784","DOIUrl":"10.1016/j.ctarc.2023.100784","url":null,"abstract":"<div><h3>Background</h3><div>For the estimated 10 million women in the United States who meet the high-risk criteria for breast cancer, evidence-based interventions may reduce the risk of breast cancer by 50–65 %. Even with substantial evidence supporting preventive medication for risk reduction, there is significant lack of uptake and adherence. The purpose of this study was to characterize the experience of women at high risk for breast cancer and define the content domain for a patient-reported outcomes (PRO) measure of symptom burden from breast cancer risk and risk reducing medication.</div></div><div><h3>Methods</h3><div>Thirty women at high risk for breast cancer and receiving risk reducing medication participated in single qualitative interviews. Content analysis was used to identify the symptom burden. An expert panel review rated the relevance of symptoms identified in the qualitative interviews to establish the items for inclusion in a PRO symptom burden measure.</div></div><div><h3>Results</h3><div>Participants had a mean age of 54.6 years; 43.3 % self-identified as Hispanic and 20.0 % self-identified as Black. Content analysis found 20 symptoms related to both risk and preventive treatment, with 8 symptoms reported by ≥ 20 % of women. All women described distress related to their risk and preventive care. Treatment-related symptoms varied based on history of risk-reducing surgery and type of endocrine therapy. Women described symptom-related interference with relationships, work, enjoyment of life, and adherence to risk reducing medication.</div></div><div><h3>Conclusions</h3><div>Women with a known high risk of breast cancer and receiving preventive care experience a unique symptom burden including multiple symptoms and functional impact related to symptoms.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100784"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R","authors":"Ben Markman ,&nbsp;Steven Kao ,&nbsp;Nick Pavlakis ,&nbsp;Victoria Bray ,&nbsp;Leisl Packer ,&nbsp;Shankar Siva","doi":"10.1016/j.ctarc.2025.100929","DOIUrl":"10.1016/j.ctarc.2025.100929","url":null,"abstract":"<div><h3>MicroAbstract</h3><div>Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 months (95% confidence interval, 17.5 to 30.8) confirming clinical benefit of durvalumab consolidation post-chemoradiotherapy in the real-world setting.</div></div><div><h3>Introduction</h3><div>The Phase 3 PACIFIC trial established post-chemoradiotherapy (CRT) durvalumab consolidation as standard treatment for patients with unresectable, stage III non-small cell lung cancer (NSCLC). We present the results from the Australian subset of the multicentric PACIFIC-R study (NCT03798535) assessing the effectiveness of durvalumab in the real-world setting.</div></div><div><h3>Patients and Methods</h3><div>Patients with unresectable, stage III NSCLC without progression following CRT, receiving at least 1 dose of durvalumab (10 mg/kg intravenously, every 2 weeks) through an early access program (EAP) between September 2017 and December 2019, were enrolled. Primary endpoints, progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan–Meier method.</div></div><div><h3>Results: As of February 7, 2022, 165 patients (median age</h3><div>67.0 years) with a median follow-up of 34.7 months were enrolled. Most received last radiation ≥42 days before durvalumab initiation (126, 79.2%) at a dose of 54 to 60 Gy (141, 88.7%). Median PFS was 22.4 months (95% confidence interval [CI], 17.5 to 30.8). The 3-year PFS and OS rates were 38.9% (95% CI, 31.0 to 46.7) and 59.1% (95% CI, 51.2 to 66.2). Pneumonitis was the most frequent adverse events of special interest (27, 16.4%); which led to treatment discontinuation in 19 (11.5%) patients.</div></div><div><h3>Conclusion</h3><div>The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100929"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response of unilateral primary lacrimal sac diffuse large B-cell lymphoma treated without radiotherapy in an adult: A rare case report and review of the literature","authors":"Suzana Sultan ,&nbsp;Tasnim Ibrahim ,&nbsp;Ali Habib ,&nbsp;Firas Hussein","doi":"10.1016/j.ctarc.2025.100897","DOIUrl":"10.1016/j.ctarc.2025.100897","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) manifests extranodally in one-third of non-Hodgkin lymphoma (NHL) cases. However, primary DLBCL of the lacrimal sac is very rare. A 54-year-old man presented with a 5-month history of right-sided epiphora. He visited three private clinics and was misdiagnosed with conjunctivitis. Later, a painless mass in the right lacrimal area prompted an MRI scan followed by a CT scan, which suggested a lacrimal sac mass. The mass was surgically excised, and histopathology and immunohistochemistry revealed DLBCL. A PET/CT scan was done instead of bone marrow biopsy, which excluded systemic lymphomatous involvement, confirming the diagnosis of primary right lacrimal sac DLBCL. The patient received six standard cycles of the R-CHOP regimen. Although no radiotherapy was used, CT findings after the completion of the 4th cycle showed a complete response (CR), which was maintained in a follow-up CT scan 2 months after chemotherapy completion. Despite the rarity of the tumor, it should be considered in the differential diagnosis of long-standing or unresponsive inflammatory conditions. Radiotherapy-free management could achieve CR in limited-stage DLBCL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100897"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway","authors":"Yu Wang ,&nbsp;Yuting Wang ,&nbsp;Huabin Gao ,&nbsp;Lin Chen,&nbsp;Shuai Zheng,&nbsp;Yongyu Chen,&nbsp;Huijuan Shi,&nbsp;Anjia Han","doi":"10.1016/j.ctarc.2025.100899","DOIUrl":"10.1016/j.ctarc.2025.100899","url":null,"abstract":"<div><div>To investigate the effect and molecular mechanism of ezetimibe on colorectal cancer (CRC), our study found that ezetimibe significantly inhibited the proliferation and progression of CRC. Further study showed that RPS6KA2 might be the target gene of ezetimibe treatment on CRC. RPS6KA2 expression was significantly lower in human CRC tissue samples and associated with T classification and vascular invasion of tumor cells. RPS6KA2 inhibited proliferation, migration, and invasion of CRC cells. The underlying mechanisms indicated that interaction between RPS6KA2 and PCSK9 was observed within the cytoplasmic compartment of CRC cells. RPS6KA2 suppressed PCSK9 and MAPK signaling pathway in CRC cells. BI-D1780 which is an inhibitor of RPS6KA2 increased PCSK9 and MAPK signaling pathway related proteins expression in SW620 cells. However, an inhibitor or stimulator of MAPK did not affect RPS6KA2 and PCSK9 expression, respectively. In vivo, CRC cells with RPS6KA2 or PCSK9 overexpression could inhibit or promote tumor growth and metastasis, respectively. PCSK9 promoted proliferation, migration, and invasion of CRC cells. PCSK9 expression was higher in human CRC samples and associated with N classification and TNM stage of CRC. In conclusion, our study firstly suggests that ezetimibe suppresses CRC progression by upregulating RPS6KA2 while downregulating PCSK9/MAPK signaling pathway.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100899"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies","authors":"Heidi A. Abouzeid ,&nbsp;Loay Kassem ,&nbsp;Xuemei Liu ,&nbsp;Ahmed Abuelhana","doi":"10.1016/j.ctarc.2025.100918","DOIUrl":"10.1016/j.ctarc.2025.100918","url":null,"abstract":"<div><div>Breast cancer (BC) is one of the leading causes of cancer-related deaths among women worldwide. Paclitaxel (PTX), a chemotherapeutic agent derived from the taxane family, is commonly used in treating BC due to its ability to disrupt microtubule dynamics and induce cell death. However, resistance to PTX presents a significant challenge, as it diminishes the drug's effectiveness and can lead to treatment failure. This review explores the mechanisms by which PTX exerts its effects and the various factors contributing to resistance. These factors include genetic mutations that affect tubulin dynamics, the role of non-coding RNAs, molecular pathways involved in chemoresistance, epigenetic changes, post-transcriptional modifications, increased activity of ABC transporters that promote drug efflux, immunosuppressive interactions within the tumor microenvironment, and resistance mediated by autophagy. This review also explores strategies to overcome PTX resistance, including molecular and genetic innovations, combination therapies, and nanotechnology-based approaches. These strategies may improve PTX efficacy and enhance treatment outcomes for BC patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100918"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143808384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer","authors":"Kibum Kim ,&nbsp;Sakil Syeed ,&nbsp;Trang Au ,&nbsp;Amber Diaz ,&nbsp;Matthew B. Schabath ,&nbsp;Amanda Cass ,&nbsp;Richard Hall ,&nbsp;Lori Pai ,&nbsp;Chenghui Li ,&nbsp;Nicole Balmaceda ,&nbsp;Alison Palumbo ,&nbsp;Autumn Carey ,&nbsp;Mumtu Lalla ,&nbsp;Matthew Henry ,&nbsp;Diana Brixner ,&nbsp;David Stenehjem","doi":"10.1016/j.ctarc.2025.100898","DOIUrl":"10.1016/j.ctarc.2025.100898","url":null,"abstract":"<div><h3>Purpose</h3><div>Osimertinib is a third-generation EGFR-TKI and preferred first-line (1L) treatment for <em>EGFR</em> positive (<em>EGFR+</em>) metastatic non-small cell lung cancer (mNSCLC). This study compared real-world clinical outcomes of 1L osimertinib versus 1st or 2nd generation EGFR-TKIs (1/2G-TKIs) in patients with EGFR+ mNSCLC.</div></div><div><h3>Methods</h3><div>Nine academic cancer centers in the US participated in the retrospective cohort study. Patients aged ≥18 years with <em>EGFR+</em> mNSCLC and treated with 1L EGFR-TKI were included. Clinical outcomes included real-world progression-free survival (rwPFS), duration of treatment (DOT), time to next treatment (TTNT), central nervous system incidence-free survival (CNS-IFS), and overall survival (OS). Multivariable regression models were used to control for differences in patient characteristics (<em>p</em> &lt; 0.1) between the osimertinib and 1/2G-TKI cohorts.</div></div><div><h3>Results</h3><div>The study included 181 osimertinib patients and 171 1/2G-TKI patients. Osimertinib had a longer rwPFS compared to 1/2G-TKIs (median PFS, 95 % confidence interval [CI]: 16.2 months (13.2–19.7) vs. 10.8 months (9.5–12.7); hazard Ratio [HR], 95 % CI: 0.60 (0.44–0.82). DOT and TTNT were significantly longer in patients treated with osimertinib versus 1/2G-TKI (HR, 95 % CI: 0.51 (0.38–0.68) for DOT; 0.54 (0.39–0.74) for TTNT). The respective HR point estimate for CNF-IFS and OS of 0.62 and 0.83 preferred osimertinib. However, small patient counts and number of events posed challenges in drawing conclusion regarding the significance of the delayed CNS-IFS or OS.</div></div><div><h3>Conclusion</h3><div>Patients treated with osimertinib had a prolonged time to progression and longer time maintain the treatment compared to 1/2G-TKI. This real-world evidence is aligned with clinical trial results.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100898"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer","authors":"Mathias H. Gramkow ,&nbsp;Camilla S. Mosgaard ,&nbsp;Jakob V. Schou ,&nbsp;Ellen Hein Nordvig ,&nbsp;Troels Gammeltoft Dolin ,&nbsp;Jakob Lykke ,&nbsp;Dorte L. Nielsen ,&nbsp;Per Pfeiffer ,&nbsp;Camilla Qvortrup ,&nbsp;Mette K. Yilmaz ,&nbsp;Ole Larsen ,&nbsp;Stig E. Bojesen ,&nbsp;Benny V. Jensen ,&nbsp;Julia S. Johansen","doi":"10.1016/j.ctarc.2025.100907","DOIUrl":"10.1016/j.ctarc.2025.100907","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoembryonic antigen (CEA) is the only prognostic circulating biomarker used in clinical practice for recurrence free (RFS), progression free (PFS) and overall survival (OS) in patients with colorectal cancer (CRC). Not all CRC tumors express this protein and carbohydrate antigen (CA)19–9 has been proposed as an adjunctive in prognostication. We aimed to test if CA19–9 yielded additional information to CEA regarding prognosis.</div></div><div><h3>Patients and methods</h3><div>We included 886 patients with CRC across eight clinical cohorts. Preoperative serum samples were collected from 376 patients with stage I-III CRC and from 510 with metastatic (m)CRC before 1st (<em>n</em> = 233)^, 3rd (<em>n</em> = 178) and 3rd/4th (<em>n</em> = 99) line chemotherapy. CA19–9 and CEA were determined by routine assays, the values were log-2 transformed and entered as variables in Cox regression models with RFS (stage I-III), PFS and OS as the outcomes, adjusted for age, sex, and site of primary tumor and mutual adjustment between CA199 and CEA. Random effects meta-analyses were conducted for stage I-III,1st line, and 3rd/4th line mCRC cohorts separately.</div></div><div><h3>Results</h3><div>Meta-analyses showed that higher pre-treatment CA19–9 and CEA were associated with shorter RFS (CA19–9: hazard ratio per doubling of concentration (HR)=1.20, 95 % confidence interval (CI) 1.05–1.38; CEA: HR=1.22, 95 % CI 1.05–1.41) in stage I-III CRC. Only higher CEA was associated with shorter OS in 1st line mCRC (HR=1.07, 95 % CI 1.00-1.07).</div></div><div><h3>Conclusion</h3><div>CA19–9 might aid in identifying patients with a high risk of recurrence after primary radical resection. Further studies are needed to validate these findings.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100907"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}